Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care

Scalable, systematic and automated process captures and monitors metrics based on patients’ treatment priorities for managing Alzheimer’s disease and related dementias

BOSTON, June 25, 2024 /PRNewswire/ — Clinical and research leaders from Linus Health, a digital health company enabling early detection of Alzheimer’s and other dementias, recently co-authored a peer-reviewed paper. The article describes a technology-enabled, scalable approach to guide clinical decisions and outcome evaluations about brain health that effectively incorporate patients’ treatment priorities.

The perspective paper, “Towards a lifelong personalized brain health program: empowering individuals to define, pursue, and monitor meaningful outcomes,” was published on June 4 in Frontiers in Neurology. Linus Health authors include lead author Stina Saunders, PhD, who leads Linus’ personalized medicine efforts, as well as Alvaro Pascual-Leone, MD, PhD, chief medical officer and co-founder, and John Showalter, MD, chief strategy officer.

“While patients may have the same neurodegenerative disease, the aspects of life that are personally meaningful and become priorities for treatment can be quite different across diverse patient backgrounds and values,” Saunders said. “As researchers and clinicians, we need to ensure that our interventions achieve clinically meaningful benefits on an individual level. Our paper describes why and how to use an evidence-based, technology-enabled tool to efficiently incorporate patients’ input and both monitor and support outcomes that truly matter to them in the long term.”

Historically, care across the spectrum of mild cognitive impairment (MCI) to dementia has lacked a widely adopted, systematized approach for integrating metrics related to clinically meaningful benefits on an individual level, the paper’s authors wrote. For example, a patient’s ability to play golf, manage finances, drive a car, write to their friends and family, and other activities varies in importance between patients, but has not been consistently included and evaluated as outcomes during clinical trials or care delivery.

In addition, while numerous standardized questionnaires have been developed over the years for gathering well-being information from patients, many face adoption obstacles such as being paper-based, time-consuming, or too broad to capture unique desired outcomes specific to patients.

As such, authors introduce the electronic Person Specific Outcome Measure (ePSOM) as an example in this area. Conceived at the University of Edinburgh in Scotland, ePSOM is now licensed to and developed by Linus Health and can efficiently incorporate unique input from patients and care partners to quantify the severity of the disability based on patients’ reported confidence in their ability to perform their desired activities. The reported assistance of care partners in helping with these activities can also support researchers and clinicians in evaluating treatment efficacy.

Such a tool can be administered online through a mobile device at home to maximize efficiency for researchers and clinicians and to improve the experience for patient-care partner dyads. Once captured, patient priorities can be easily monitored throughout the duration of a clinical trial or followed longitudinally in clinical settings. In a healthcare delivery environment, patient and caregiver input can be combined with other brain health factors and lifestyle questions to generate a personalized Brain Health Action Plan, a patient education tool that highlights areas of attention and actionable lifestyle and health interventions to support better brain health.

“Linus Health’s digital cognitive assessment platform can be scaled to support the management of thousands of patients across a health system or to enable large, multi-centered studies. However, our ultimate focus is to empower each individual to define their personal brain health priorities and support them to achieve them,” Pascual-Leone said. “Our paper in Frontiers in Neurology lays out the practical and feasible approach we use to define, monitor and protect, in healthcare and clinical research, those hugely important patient-centered brain health priorities that need to be our compass throughout the patient and care partner journey.”

Contact Linus Health at info@linus.health to learn more about this tech-enabled approach to capture clinically meaningful benefits to advance both clinical care and research activities in brain health.

About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier, and healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow us on LinkedIn.

Media Contact
Tara Stultz (Amendola for Linus Health)
440-225-9595
tstultz@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/linus-health-introduces-person-centered-approach-to-establish-clinically-meaningful-benefits-and-personalized-brain-health-care-302181804.html

SOURCE Linus Health

Staff

Recent Posts

ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan from Runway Growth Capital LLC

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN…

3 hours ago

LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders

BOUCHERVILLE, Québec, June 28, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB)…

3 hours ago

Lowell Farms Inc. Announces Change of Chief Financial Officer

SALINAS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL;…

3 hours ago

PetVivo Reports Reports Fiscal 2024 Results

MINNEAPOLIS, MN, US, June 28, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW),…

3 hours ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or…

3 hours ago

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a…

3 hours ago